The purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention.
Study Details
Internal Title:
HYPO507286114
PCH IRB Number:
S-IRB-24-0
Clinical Trials Government Identifier:
NCT06042257
Diagnoses & Treatments:
Guanfacine, Down Syndrome, Hyperactivity, Trisomy 21, HYP01
Study Type:
Clinical Trial
Eligibility:
6-12 years of age with Down syndrome (DS).
Enrollment Status:
Open
Phase:
II